Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.80 |
| ▸ | JAK1 | P23458 | 12/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.58 |
| ▸ | JAK3 | P52333 | 7/20 | 0.58 |
| ▸ | TYK2 | P29597 | 6/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 3/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.51 |
| ▸ | PAK4 | O96013 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | LTK | P29376 | 2/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29780369 | 1.00 | JAK2 (0.80) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL13695710 | 0.97 | JAK2 (0.80) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL4115196 | 0.92 | JAK2 (0.70) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL13695658 | 0.90 | JAK2 (0.69) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL13064685 | 0.89 | JAK2 (0.78) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL859886 | 0.89 | JAK2 (1.00) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL848835 | 0.89 | JAK2 (1.00) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL860196 | 0.89 | JAK2 (1.00) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL29540692 | 0.88 | JAK2 (0.64) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL98856 | 0.88 | JAK2 (0.64) | JAK2JAK1HDAC6JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643312-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | Incyte Holdings Corporation (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3600440-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | Sienna Biopharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020023389-A1 | REDUCED EXPOSURE COMPOSITIONS MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| EP-2432472-B1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | INCYTE HOLDINGS CORP (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018175340-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175315-A1 | POLYMER CONJUGATES OF STAUROSPORINE DERIVATIVES HAVING REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| US-9623029-B2 | 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160067253-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION (US) | 2016-03-10 | — | — | US | disclosed |
| US-20140073657-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | INCYTE CORPORATION | 2014-03-13 | — | — | US | disclosed |
| CN-102458411-A | 3- [4- (7H-pyrrolo [2,3-D ] pyrimidin-4-yl) -1H-pyrazol-1-yl ] octane-or heptane-carbonitriles as JAK inhibitors | INCYTE CORP | 2012-05-16 | — | — | CN | disclosed |
| EP-2432472-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | Incyte Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2432472-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | Incyte Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135621-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298355-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298355-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885HDAC6 1491/4885 |
| US-20160067253-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885HDAC6 1491/4885 |
| US-20140073657-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885HDAC6 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.